Epigallocatechin-3-gallate ( DrugBank: Epigallocatechin, Epigallocatechin-3-gallate )

3 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	1
28	Systemic amyloidosis	1
85	Idiopathic interstitial pneumonia	2

8. Huntington disease

Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01357681 (ClinicalTrials.gov)	September 2011	19/5/2011	Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)	Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -	Huntington Disease	Drug: (2)-epigallocatechin-3-gallate (EGCG);Drug: Placebo	Charite University, Berlin, Germany	NULL	Completed	18 Years	N/A	Both	54	Phase 2	Germany

28. Systemic amyloidosis

Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02015312 (ClinicalTrials.gov)	April 2013	18/11/2013	A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)	A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)	Light Chain (AL) Amyloidosis;Cardiac Involvement	Drug: Epigallocatechin-3-gallate (EGCG);Drug: Placebo	Florian Michel	German Federal Ministry of Education and Research	Completed	18 Years	N/A	All	38	Phase 2	Germany

85. Idiopathic interstitial pneumonia

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05195918 (ClinicalTrials.gov)	March 1, 2023	2/12/2021	Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients	Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect	Idiopathic Pulmonary Fibrosis	Combination Product: EGCG 300 mg + Nintedanib;Combination Product: EGCG 300 mg + Pirfenidone;Combination Product: Placebo 2 capsules + Nintedanib or Pirfenidone;Combination Product: EGCG 600 mg + Nintedanib;Combination Product: EGCG 600 mg + Pirfenidone;Combination Product: Placebo 4 capsules + Nintedanib or Pirfenidone	Hal Chapman	University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;University of Washington	Not yet recruiting	40 Years	85 Years	All	50	Phase 1	United States
2	NCT03928847 (ClinicalTrials.gov)	December 1, 2017	18/4/2019	Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.	Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.	Idiopathic Pulmonary Fibrosis	Drug: Epigallocatechin-3-gallate (EGCG)	Hal Chapman	National Heart, Lung, and Blood Institute (NHLBI)	Completed	40 Years	70 Years	All	35	Early Phase 1	United States